In the wake of yesterday’s pharma-deal madness (Novartis swapping assets with GlaxoSmithKline and selling its animal health division to Eli Lilly; Valeant and Bill Ackman making a hostile bid for Botox-maker Allergan), Bernstein analyst Geoffrey Porges sent a note out to investors asking what it might all mean for biotech […]
Should Amgen Break Itself Up?
Nessun commento:
Posta un commento